Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Satoshi Motoya

Showing results (41-50 of 89) with videos related to

Pageof 9
Sort By:
Surgery Today|February 1, 2018
Postoperative therapy with infliximab for Crohn's disease: a 2-year prospective randomized multicenter study in JapanKouhei Fukushima, Akira Sugita, Kitaro Futami, et al.
Gastro Hep Advances|August 12, 2024
Shorter Crohn's Disease Duration Is Associated With Better Clinical and Endoscopic Outcomes With Risankizumab in Phase 3 StudiesLaurent Peyrin-Biroulet, Jean-Frederic Colombel, Edouard Louis, et al.
Digestion|January 17, 2021
Week 2 Symptomatic Response with Vedolizumab as a Predictive Factor in Japanese Anti-TNFα-Naive Patients with Ulcerative Colitis: A post hoc Analysis of a Randomized, Placebo-Controlled Phase 3 TrialMasakazu Nagahori, Kenji Watanabe, Satoshi Motoya, et al.
BMC Gastroenterology|November 23, 2019
Safety and effectiveness of granulocyte and monocyte adsorptive apheresis in patients with inflammatory bowel disease in special situations: a multicentre cohort studySatoshi Motoya, Hiroki Tanaka, Tomoyoshi Shibuya, et al.
Intestinal Research|May 14, 2016
Pregnancy outcome in women with inflammatory bowel disease treated with anti-tumor necrosis factor and/or thiopurine therapy: a multicenter study from JapanShunsuke Komoto, Satoshi Motoya, Yuji Nishiwaki, et al.
The Lancet. Gastroenterology & Hepatology|April 22, 2021
Discontinuation of infliximab in patients with ulcerative colitis in remission (HAYABUSA): a multicentre, open-label, randomised controlled trialTaku Kobayashi, Satoshi Motoya, Shiro Nakamura, et al.
Crohn'S & Colitis 360|May 7, 2024
Effectiveness and Persistency of Ustekinumab Treatment for Ulcerative Colitis: A Phoenix retrospective Cohort StudyKatsuyoshi Ando, Mikihiro Fujiya, Nobuhiro Ueno, et al.
Inflammatory Bowel Diseases|October 12, 2011
Retrieval of serum infliximab level by shortening the maintenance infusion interval is correlated with clinical efficacy in Crohn's diseaseToshifumi Hibi, Atsushi Sakuraba, Mamoru Watanabe, et al.
Journal of Gastroenterology and Hepatology|December 21, 2013
Use of capsule endoscopy in patients with Crohn's disease in Japan: a multicenter surveyMotohiro Esaki, Takayuki Matsumoto, Kenji Watanabe, et al.
Intestinal Research|March 10, 2022
Efficacy and safety of filgotinib as induction and maintenance therapy for Japanese patients with moderately to severely active ulcerative colitis: a post-hoc analysis of the phase 2b/3 SELECTION trialToshifumi Hibi, Satoshi Motoya, Tadakazu Hisamatsu, et al.
Pageof 9

Showing results (41-50 of 89) with videos related to

Sort By:
Pageof 9
Surgery Today|February 1, 2018
Postoperative therapy with infliximab for Crohn's disease: a 2-year prospective randomized multicenter study in JapanKouhei Fukushima, Akira Sugita, Kitaro Futami, et al.
Gastro Hep Advances|August 12, 2024
Shorter Crohn's Disease Duration Is Associated With Better Clinical and Endoscopic Outcomes With Risankizumab in Phase 3 StudiesLaurent Peyrin-Biroulet, Jean-Frederic Colombel, Edouard Louis, et al.
Digestion|January 17, 2021
Week 2 Symptomatic Response with Vedolizumab as a Predictive Factor in Japanese Anti-TNFα-Naive Patients with Ulcerative Colitis: A post hoc Analysis of a Randomized, Placebo-Controlled Phase 3 TrialMasakazu Nagahori, Kenji Watanabe, Satoshi Motoya, et al.
BMC Gastroenterology|November 23, 2019
Safety and effectiveness of granulocyte and monocyte adsorptive apheresis in patients with inflammatory bowel disease in special situations: a multicentre cohort studySatoshi Motoya, Hiroki Tanaka, Tomoyoshi Shibuya, et al.
Intestinal Research|May 14, 2016
Pregnancy outcome in women with inflammatory bowel disease treated with anti-tumor necrosis factor and/or thiopurine therapy: a multicenter study from JapanShunsuke Komoto, Satoshi Motoya, Yuji Nishiwaki, et al.
The Lancet. Gastroenterology & Hepatology|April 22, 2021
Discontinuation of infliximab in patients with ulcerative colitis in remission (HAYABUSA): a multicentre, open-label, randomised controlled trialTaku Kobayashi, Satoshi Motoya, Shiro Nakamura, et al.
Crohn'S & Colitis 360|May 7, 2024
Effectiveness and Persistency of Ustekinumab Treatment for Ulcerative Colitis: A Phoenix retrospective Cohort StudyKatsuyoshi Ando, Mikihiro Fujiya, Nobuhiro Ueno, et al.
Inflammatory Bowel Diseases|October 12, 2011
Retrieval of serum infliximab level by shortening the maintenance infusion interval is correlated with clinical efficacy in Crohn's diseaseToshifumi Hibi, Atsushi Sakuraba, Mamoru Watanabe, et al.
Journal of Gastroenterology and Hepatology|December 21, 2013
Use of capsule endoscopy in patients with Crohn's disease in Japan: a multicenter surveyMotohiro Esaki, Takayuki Matsumoto, Kenji Watanabe, et al.
Intestinal Research|March 10, 2022
Efficacy and safety of filgotinib as induction and maintenance therapy for Japanese patients with moderately to severely active ulcerative colitis: a post-hoc analysis of the phase 2b/3 SELECTION trialToshifumi Hibi, Satoshi Motoya, Tadakazu Hisamatsu, et al.
Pageof 9